98%
921
2 minutes
20
Novel implant systems have design modifications that seek to improve total knee arthroplasty (TKA) survivorship. We evaluated overall and cause-specific revision risk for a newer generation implant system compared with its predecessor from the same manufacturer. We conducted a cohort study using data from the United States-based Kaiser Permanente Total Joint Replacement Registry. Adult patients who underwent primary, fully cemented, fixed-bearing TKA for osteoarthritis between 2009 and 2022 were identified. Only two implant systems from the manufacturer were included: the newer generation ( = 22,287) and the older generation ( = 37,105). Multivariable Cox regression was used to evaluate overall and cause-specific aseptic revision risk. In the adjusted analyses, no difference in risk was observed for the newer compared with older generation system in the first 4-year follow-up (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.74-1.19); however, a higher risk was observed after 4-year follow-up (HR = 2.09, 95% CI = 1.41-3.08). This higher risk was due to loosening (within 4 years: HR = 0.90, 95% CI = 0.59-1.37; after 4 years: HR = 2.88, 95% CI = 1.84-4.51); no differences were observed for other revision reasons. When considering constructs utilizing different trays of the newer generation system, the higher risk of revision for loosening was observed only when the first iteration of the tray was used (HR = 1.94, 95% CI = 1.37-2.77); no difference was observed for constructs utilizing the subsequent iterations of the tray, which underwent design changes, when compared with the older generation TKA system (HR = 0.45, 95% CI = 0.20-1.01). We found no survivorship advantage with a newer TKA design compared with a preceding design from the same manufacturer. The higher risk of revision for loosening in the newer generation constructs was limited to those utilizing the first tray iteration, which is now discontinued by the manufacturer. The higher revision risk was not observed with subsequent iterations of the newer generation construct relative to the older generation. LEVEL OF EVIDENCE: Level III.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2664-7627 | DOI Listing |
Indian J Dermatol
September 2025
Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
Oncogenic pruritus or malignancy associated pruritus is an emerging cause of systemic pruritus in patients with malignancies. It is a debilitating condition and worsens the patient's quality of life, often interfering with their palliative care. Oncogenic pruritus can arise de-novo in such patients due to release of pruritogens and other inflammatory mediators from tumour cells into blood stream, or it may present as a component of paraneoplastic syndrome.
View Article and Find Full Text PDFSci Total Environ
September 2025
Department of Geological Sciences and Geological Engineering, Queen's University, 99 University Ave, K7L 3N6 Kingston, Ontario, Canada.
Hyperspectral data have been overshadowed by multispectral data for studying algal blooms for decades. However, newer hyperspectral missions, including the recent Plankton, Aerosol, Cloud, ocean Ecosystem (PACE) Ocean Color Instrument (OCI), are opening the doors to accessible hyperspectral data, at spatial and temporal resolutions comparable to ocean color and multispectral missions. Simulation studies can help to understand the potential of these hyperspectral sensors prior to launch and without extensive field data collection.
View Article and Find Full Text PDFDiabetes Metab Res Rev
September 2025
Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Bari, Italy.
Overweight and obesity represent common chronic metabolic disorders in the general population, and observed trends describe a substantial growth in the prevalence of weight excess also among individuals with type 1 diabetes (T1D), the so-called 'lean phenotype' of diabetes. The sharp rise of weight excess and obesity-related cardio-nephron-metabolic burdens observed in T2D is expected to produce similar consequences in T1D, leading to the urgent need to endorse therapeutic protocols as in most parts of the World no adjunctive treatments are approved for T1D, making weight excess management challenging in these individuals. The notable results shown by newer glucagon-like peptide 1 receptor agonists (GLP-1RAs) and emerging dual agonists, especially while managing cardio-metabolic burdens, in T2D have encouraged fervent anecdotal and non-anecdotal research also in T1D, indicating that non-insulin injective agents can be effective and safe.
View Article and Find Full Text PDFCurr Probl Cardiol
September 2025
Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA. Electronic address:
HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody-drug conjugates.
View Article and Find Full Text PDFHeart Lung Circ
September 2025
Department of Cardiology, The Prince Charles Hospital, Brisbane, Qld, Australia; Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Herston, Qld, Australia.
Background: The fourth-generation MitraClip G4 system is the latest version of the transcatheter edge-to-edge repair (TEER) system for mitral regurgitation (MR).
Aim: This study aimed to evaluate the effectiveness of the MitraClip G4 in the reduction of MR compared to the early-generation MitraClip.
Method: We performed a retrospective analysis of consecutive patients undergoing TEER for MR with either the early-generation or newer-generation MitraClip G4 from a single-centre registry.